Avalo Therapeutics, Inc.
HealthcareNASDAQ:AVTX · NASDAQ Capital Market
+$1.09 today
Vol 1.10M · Avg 1.57M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$78.3M -122.8% | -$35.1M -11.4% | -$31.5M +24.3% | -$41.7M +50.6% | -$84.4M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $344.0K +103.6% | $169.0K +7.0% | $158.0K -4.8% | $166.0K -90.0% | $1.7M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $165.0K +44.7% | $114.0K +714.3% | $14.0K -50.0% | $28.0K +27.3% | $22.0K | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $13.6M +132.8% | $5.9M +68.3% | $3.5M -54.0% | $7.6M -7.6% | $8.2M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $3.8M +181.6% | -$4.7M +49.0% | -$9.2M -15300.0% | -$60.0K -102.1% | $2.8M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 +100.0% | -$475.0K -126.6% | $1.8M -38.1% | $2.9M +157.8% | $1.1M | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 -100.0% | $20.0K +11.1% | $18.0K +151.4% | -$35.0K | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$146.0K +10.4% | -$163.0K +93.3% | -$2.4M -400.2% | -$487.0K -161.2% | $796.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $4.0M +198.0% | -$4.1M +52.7% | -$8.6M -248.3% | -$2.5M -357.1% | $961.0K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $8.8M +157.5% | -$15.4M -337.9% | $6.5M -10.6% | $7.2M +809.2% | $794.0K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$51.5M -4.9% | -$49.1M -59.9% | -$30.7M -14.7% | -$26.8M +62.3% | -$70.9M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | $0 | $0 +100.0% | -$158.0K -66.3% | -$95.0K +15.9% | -$113.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 -100.0% | $356.0K | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$113.7M | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $31.3M | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $690.0K | $0 -100.0% | $25.0K | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$81.7M -23055.1% | $356.0K +367.7% | -$133.0K -40.0% | -$95.0K +15.9% | -$113.0K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 +100.0% | -$21.2M -43.5% | -$14.8M -145.0% | $32.9M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $15.1M -86.9% | $115.6M +150.2% | $46.2M +43095.3% | $107.0K -99.9% | $71.9M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$510.0K -100.8% | $60.2M +89786.6% | $67.0K | $0 -100.0% | $1.9M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $14.6M -91.7% | $175.8M +602.2% | $25.0M +270.4% | -$14.7M -113.8% | $106.8M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 -100.0% | $96.0K | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$118.6M -193.3% | $127.1M +2303.2% | -$5.8M +86.1% | -$41.4M -215.9% | $35.8M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$51.5M -4.9% | -$49.1M -59.1% | -$30.8M -14.9% | -$26.8M +62.2% | -$71.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Inventiva S.A.
NASDAQ:IVA
$200.13M
Coherus Oncology, Inc.
NASDAQ:CHRS
$171.37M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
$100.28M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
SEC Filings
Recent regulatory filings
No filings found.
Does AVTX generate free cash flow?
Avalo Therapeutics, Inc. (AVTX) generated -$51,458,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does AVTX produce?
Operating cash flow was -$51,458,000.00, before capital expenditures of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.